According to Zhitong Finance APP, Bank of Communications International released a research report stating that HANSOH PHARMA (03692), as a leading prescription drug company with the highest proportion of innovative drugs and most advanced overseas expansion among peers, maintains a "BUY" rating and industry key recommendation. The target price has been raised from HK$33 to HK$48, equivalent to 2.2 times the predicted dynamic price-to-earnings ratio for next year.

Bank of Communications International noted that HANSOH PHARMA's product sales continued strong double-digit growth in the first half of the year, while BD (business development including product licensing, acquisitions, partnerships and strategic expansion) collaborations in ADC and GLP-1 product series continued to contribute considerable partnership revenue. The firm expects Ameile's annual sales still have growth potential of RMB 3-4 billion, and is optimistic about the performance contribution from product internationalization after BD normalization.

The report indicated that HANSOH PHARMA has raised its full-year revenue guidance to high double-digit percentage growth, up from the previous double-digit guidance. Sales guidance for Ameile and overall innovative drugs remains at RMB 6 billion and RMB 10 billion respectively. The company will increase R&D investment in the second half of the year, with R&D expenses expected to grow by more than 38%, and full-year growth of more than 30%.